Structural barriers in access to medical marijuana in the USA-a systematic review protocol

There are 43 state medical marijuana programs in the USA, yet limited evidence is available on the demographic characteristics of the patient population accessing these programs. Moreover, insights into the social and structural barriers that inform patients’ success in accessing medical marijuana are limited. A current gap in the scientific literature exists regarding generalisable data on the social, cultural, and structural mechanisms that hinder access to medical marijuana among qualifying patients.

Perioperative Patient Beliefs Regarding Potential Effectiveness of Marijuana (Cannabinoids) for Treatment of Pain: A Prospective Population Survey

Cannabinoids have an expanding presence in medicine. Perioperative patients’ perceptions of the effectiveness of these compounds, and acceptance if prescribed for pain, have not been previously described. Patients generally believe that marijuana could be at least somewhat effective for the management of pain and are willing to use cannabinoid compounds for this indication, if prescribed by a physician.

Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads

Additional parts of the cannabis plant provide a wide and distinct variety of other compounds of pharmacological interest, including the triterpenoid friedelin from the roots, canniprene from the fan leaves, cannabisin from seed coats, and cannflavin A from seed sprouts. This chapter will explore the unique attributes of these agents and demonstrate how cannabis may yet fulfil its potential as Mechoulam’s professed “pharmacological treasure trove.”

Medical Cannabinoids in Children and Adolescents: A Systematic Review

Legalization of medical marijuana in many states has led to a widening gap between the accessibility and the evidence for cannabinoids as a medical treatment. Evidence for benefit was strongest for chemotherapy-induced nausea and vomiting, with increasing evidence of benefit for epilepsy. At this time, there is insufficient evidence to support use for spasticity, neuropathic pain, post-traumatic stress disorder, and Tourette syndrome. Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents